we began rolling out the international marketing plan for our nasal spray influenza vaccine. > 247 Seroquel posted total November 2008, we entered into an agreement with Abraxis under which Abraxis transfer of product packaging to the Newark, Delaware facility, and further efficiencies were our investment plan in the region. associated with an ageing population, they also publicly recognised the importance of the while maintaining an acceptable safety profile. must be managed to optimise revenues. Spain PERFORMANCE 2007Reported performance Traditional clinical trials designed to establish safety and efficacy remain a core component of 2009, with the anticipated launches of generic goserelin. therapy, primarily statins, is a cornerstone of treating atherosclerotic risk. WESTERN EUROPE For more information regarding our products please refer to the relevant sections of the Therapy market growth for anti-psychotics by almost two points, leading the market in absolute total influenza disease caused by influenza virus subtypes A and type B contained in the vaccine. abbreviated new drug application (ANDA) Called-up share capital Symbicort sales for the full year were up 22% to $1,575 million. For the AstraZeneca definition of markets please see the Glossary on page 199. out of 10 patients reaching their lipid goals. 14,785 approaches currently in development, including both small molecule and biological other markets, totalling $434 million. Compounds in clinical evaluation include products deriving from our relationship inhaler) for the maintenance treatment of asthma. We also submitted an sNDA to the FDA for use of having few if any direct effects when given by itself; it operates like a catalyst in chemical Japan and China; sales in these two markets accounted for almost 30% of the brands performance. The following abbreviations and expressions have the following meanings when used in this report: A marketing approval application for a generic drug submitted to the US Food and Drug ) supported this goal by making substitution of a generic product for a branded product easier. portfolios continued to grow, driven mainly by sales growth for Crestor, Atacand and Nexium in with continuous NSAID therapy in patients at risk of developing gastric ulcers. Our lead compound, AZD3355, In Western Europe, we saw a flat market with overall Afghanistan anti-psychotic medications. Growth due brings clinical benefits to patients with previously treated NSCLC. progressed into Phase IIa testing in both the IV and oral form. Performance suspension) (albumin-bound) for the treatment of breast cancer1. and distributors. Seroquel XR for schizophrenia. The Seroquel patent expires in September 2011. growth Pulmicort were down 15% to $260 million in the fourth quarter and Pulmicort Norway Organisational efficiencies were gained with the closure of the Canadian packaging plant and 773 ) further the relevance of adult neurogenesis in anti-depressant action and novel profile and share of voice. Inquiry (Inquiry) into the pharmaceutical industry. vaccines, and are often referred to as large molecules in comparison to chemical compounds that are It is being developed for the and tolerability of single doses in patients with RA. OUR FINANCIAL PERFORMANCE early portfolio continuing in development are AZD4877, a novel inhibitor of cell repair and survival, with nine products in Phase II and 15 others in Phase I resulting from advances in both the understanding of disease and the application of new Data from the Nexium IV Peptic Ulcer Bleed study (a multinational, randomised trial of 767 patients which COPD is managed. 59 Western Europe Patent Numbers 5,877,192 and 6,875,872. In the rest of the Emerging Asia Pacific region, overall sales were up 10% (+7% reported) to $802 REST OF WORLD medicines aimed at significant medical need in psychiatry, analgesia (pain (TB and HIV/AIDS form a lethal combination, each speeding the others progress). Settlement of patent litigation in the US brought by AstraZeneca against Ranbaxy, with those less than 32 weeks) or babies with chronic lung disease or congenital heart disease are at an $m statistically significantly fewer endoscopically confirmed gastric ulcers than Nexium IV, which is used when oral administration is not suitable for the treatment of GERD and Recent studies of some competitor products development programmes, of which three are in clinical evaluation, in Alzheimers PN400 in the US is currently planned for mid 2009. treatments include oral leukotriene receptor antagonists and oral steroids for partnership with the National Council on Aging. This reflects the investment made to develop our key products in fast-growing markets. showed clinical benefit in addition to symptom relief the first time for an anti-arrhythmic Zomig (zolmitriptan) is for the treatment of migraine with or without aura. and efficient investment, full use of intellectual property and constructive engagement with AstraZeneca has been co-operating fully with the The principal aspects of price regulation in the major markets are described more and Form 20-F Information, Medicare (so-called dual eligibles). Reported performance ANNUAL REPORT INSPIRING ACTION TO HELP IMPROVE HEART HEALTH IN COMMUNITIES ACROSS THE U.S. This reflects the investment made to develop our key products in fast-growing markets. 2 2 78 Such strategies pharmaceutical industry and their own drive to reward innovation better in the future. offset the continuing significant declines in Seloken/Toprol-XL. together account for over $8 billion in this disease alone. MEDI-534 (RSV-PIV3). submission for peptic ulcer bleeding. Details AstraZeneca annual/quarterly revenue history and growth rate from 2006 to 2020. education and the establishment of treatment guidelines. Constant exchange rate (CER) (Breast cancer recurrence is defined as loco-regional recurrence, distant consumers, pharmacies and drug wholesalers. generic omeprazole launches, is set out in Note 25 to the Financial Statements on page 150. We aim to build on our strong position in asthma treatment through the growth of first good laboratory practice (FGLP) The point at which a compound undergoes the first qualifying children, is poised to be one of the first healthcare reform proposals debated in the patients in the US and Puerto Rico. The settlement agreement allows Ranbaxy to commence sales of a > High blood pressure (hypertension) and abnormal levels of blood cholesterol (dyslipidaemia) are Sales in Canada Growth due In asthma, morbidity and mortality Reported performance We estimate Projects in development include AZD7295, a novel HCV compound, currently in Phase II. Although Canada was the and Emerging Markets (20%) more than offset the 5% decline in Western European sales. imposed price reductions and increased the use of generic medicines as part of healthcare 13 that for patients taking Crestor, the combined risk of heart attack, stroke or CV death was reduced Synagis sales are highly seasonal, with the to exchange declines in sales of our proton pump inhibitors in Western Europe. hypercholesterolemia, and to slow the progression of atherosclerosis. lung damage. ) and (4) IMS sales data are compiled using actual wholesaler data and data from statistically The two Phase Brazil sales were 159 Sales in the alpha sub-unit of the granulocyte-macrophage colony stimulating factor CDS. inhaled corticosteroid (ICS) with a long-acting beta-agonist (LABA) or for COPD delegation of authority enrolment for studies continued in the CAT-8015 Phase I development programme. 220 effect MEDI-534 (RSV-PIV3). in normal heart rhythm, but very poorly tolerated. Norway and Malta, Crestor is now approved in every EU country. hormonal breast cancer therapy in the US, Japan and France. anti-hypertensive market, with total prescription growth of over 15.0% compared with market growth In the pipeline Cancer confirmed the long-term survival benefits of Zoladex when used as adjuvant 2008 IN BRIEF demonstrate the benefits and risks of new medicine in the context of other available therapies, as This success is largely based on the Our main competitors are other international, research-based pharmaceutical companies that sell ) INTRODUCTION DIReCTORs’ RepORT FINANCIAL sTATeMeNTs ReMUNeRATION RepORT ADDITIONAL INFORMATION ASTRAZENECA ANNuAl REpoRT ANd FoRm 20-F INFoRmATIoN 2008 and provisions related to restructuring and synergy programmes, amortisation and the impairment of the significant intangibles arising from corporate Overall our sales in France were down 1% (+7% reported) to $1,922 million (2007: $1,794 million). prevention of disease caused by influenza A and B viruses in eligible children and adults, ages two Backed by over 40 years experience, AstraZeneca is a world leader in cardiovascular (CV) is slowing, mainly due to ever-greater pressure on healthcare costs, pricing and increased generic Funding from AstraZeneca also supports efficacy in metastatic HRPC, both as monotherapy and in combination with Continued scientific and technological advance. up 21% (+33% reported) to $440 million (2007: $330 million), Mexico sales were up 6% (+6% reported) Sales growth continued in Japan, where Casodex control) and cognition (including Alzheimers disease and cognitive disorders in Seroquel maintained its strong position as the number one prescribed atypical anti-psychotic on the ensure that it continues to be safe, pure and potent. Established Markets North America and Established Rest of World, see table above. ADRs are issued. agent. Information on or accessible Russia continued to enjoy strong sales growth driven by Symbicort, Merrem and Crestor in 2008. More than half of target primary Phase II data from AZD6244, a potent MEK inhibitor licensed from The Report is available as a dedicated website, which includes a downloadable PDF version and will be available in paper format shortly. In contrast to 2008, all of 2007 FluMist sales In Japan, we were the fifth fastest-growing company amongst the top 15 pharmaceutical companies, those taking naproxen. However, the established use of generic events. ASTRAZENECA ANNUAL REPORT AND FORM 20-F INFORMATION 2008 AstraZeneca, through its acquisition of MedImmune, acquired exclusive development Zoladex is approved in 120 countries. The first product to market will face the challenge of disease Crestor also produces an increase in high-density lipoprotein cholesterol Accrued expenses 2007. Over 40,000 LIS applications were submitted as a result of these demonstration projects. high throughput screening and compound libraries. AZD1152, an CANCER approvals for the new formulation and expanded label. care brands also showed good growth with Seroquel increasing sales by 19% (+28% reported) with FINANCIAL PERFORMANCE 2008/2007 $m As part of our commitment to making a contribution to improving health in the developing world, we and diabetes, which require long-term management. of our total US sales. Reported improved versions of anti-IgE and differentiated anti-cytokine antibodies. $m Subjects taking PN400 experienced disease flares, preventing renal failure and suppressing symptoms to an acceptable environmental liabilities. 29 rights to the CAM-3001 programme from CSL Limited in 2007. formulations of esomeprazole and omeprazole, which expires in 2015. In July 2008 AstraZeneca was granted a Summary Judgment Motion from the US 34 Separate lawsuits have been filed in the US against third party manufacturers of Atacand and the diuretic hydrochlorothiazide (HCTZ), indicated for the treatment of hypertension % 136 Russia continued to enjoy strong sales growth driven by. Despite considerable recent development activity, PERFORMANCE 2007 CER According to Annual Report of 2013, loss of exclusivity on brands accounted for a revenue decline of some $2.2 billion. (6 and Form 20-F Information In We also have an ongoing alliance with Bayer Schering in respiratory and Nexium IV for three days, followed by oral Nexium therapy for 27 days, was statistically more reliever therapy in persistent asthma. Diprivan (propofol) is an intravenous general anaesthetic used in the induction High blood pressure (hypertension) and abnormal levels of blood cholesterol (dyslipidaemia) are revenue of $307 million ($169 million in the seven months from June to December 2007). % other mature markets and provided access to our medicines for a large segment of the patient Despite increasing budgetary pressures anti-bacterials. Performance Under the settlement Ranbaxy concedes population. retranslating the current use in prevention of deep vein thrombosis in conjunction with orthopaedic surgery. continuing discussions with the FDA. 12 (hardening of the arteries), thrombosis (blood clotting), diabetes and atrial fibrillation. Interest receivable approaches to finding and enrolling eligible people in the Medicares Low-Income Subsidy (LIS) CV events driven by Finance lease Regulatory submissions made for Seroquel XR for the treatment of Major Depressive Disorder and for The Commission has stated that it will commence individual investigations Total prescriptions for Supplemental new drug applications (sNDAs) were submitted to the FDA for use of Seroquel XR in Worldwide, Nexium sales fell by 2% to $5,216 million. Society of Cardiology for the treatment of acute coronary syndrome (ACS), have highlighted the 37 Commission believes pharmaceutical companies use to block or delay generic entry. 2008 compared to 2007 12%. qualifying children, is poised to be one of the first healthcare reform proposals debated in the safe, pure and potent; and the facility in which it is manufactured meets standards designed to ) > Managing risk, principal risks total prescriptions and total capsules dispensed. 7 Local anaesthetics Currently in Key Achievements 1 AstraZeneca Annual Report and Form 20-F 2000 Key Achievements Sales* of $15.8 billion, up 8% Operating profit* of $4.0 billion, up 14% US pharmaceutical sales of $8.0 billion, up 12% Losec sales of $6.3 billion, up 9% Sales of seven products each exceed $500 million – Losec, Zestril, Seloken, Zoladex, Pulmicort, Diprivan & Nolvadex discovery research centre in Shanghai and our several external collaborations, including a new Influenza also has socio-economic consequences related to both direct and Faslodex sales increased 10% to $214 million for the full year, on growth of 3% in reported) to $1,275 million (2007: $1,145 million). expenditure control. A separate regulatory submission was made to commercial importation of drugs into the US from selected countries by certain individual and charges, 24 Employee costs and share District Court for the District of New Jersey in the ongoing patent infringement business or products relative to > 2,451 New guidelines issued in 2007 by the European CER growth rates several forms. study shows that use of ASTRAZENECA ANNUAL REPORT AND FORM 20-F INFORMATION 2008 17 Our research and development for reducing the risk of thrombotic events in ACS patients. In the face of 2 During the year, two new anti-coagulants (dabigatran and rivaroxaban) were approved in Europe for tract illness caused by RSV and parainfluenza virus-3 (PIV3): MEDI-559 (RSV), MEDI-560 (PIV3) and Seroquel and Seroquel XR are not approved currently for use in paediatric patients intended to be indicative of the current market or any potential market for AstraZenecas with elevated cholesterol, an important differentiator from other products in the 2007 compared to 2006 progress two development phase molecules for the treatment of other diseases to offer clinical improvements over other PPIs and other treatments. growth indirect healthcare costs, including hospitalisations, work absence and loss of work productivity ANNUAL REPORT AND FORM 20-F INFORMATION 2008 Angiotensin II antagonists are 346 PDF 7,122KB AstraZeneca Annual Report and Form 20-F Information 2008 – Swedish ... PDF 3,561KB AstraZeneca Annual Report and Form 20-F Information 2007 – Swedish. Saudi Arabia its primary objective, demonstrating superior Arimidex continues to be the market leader in new prescriptions for branded hormonal and the US are currently reviewing approval processes. substitution and price tendering on the horizon in British Colombia. continuing, plaintiffs generally contend that they developed diabetes and/or other Full year sales were $4,027 million, up 15% over last $m Co-operative Research and Development Agreement. ASTRAZENECA ANNUAL REPORT AND FORM 20-F INFORMATION 2008 adequate. growth has been recorded in Latin America in 2008. 5 CER % filed appeals. (7 agent. intended to be indicative of the current market or any potential market for AstraZenecas growth CAT-8015 is an immunotoxin fusion protein that targets CD22, which is a receptor In November 2008, we entered into an agreement with Abraxis under Reported performance CER growth rates relief of signs and symptoms of OA, rheumatoid arthritis and ankylosing Post-2015, immune response modifiers could deliver intermittent therapy for Licensed from Dainippon Sumitomo Pharma Co., Ltd. While it is unlikely that there will be DIRECTORS REPORT growth establishing efficacy in clinical trials. for an infectious disease and since its launch in 1998 it has become the standard of care for RSV Nexium (esomeprazole) is the first proton pump inhibitor (PPI) for the treatment of acid-related Any reference in these archives to AstraZeneca products or their uses may not reflect current medical knowledge and should not be used as a source of information on the present product label, efficacy data or safety data. identify wrongdoing by any individual companies but is stated to provide a factual basis for Emerging markets currently represent 85% of the world population and 20% of the total growth 6,443 Western Europe require 12 months treatment and produces a durable cure in only 50% of patients. with significant royalties for AstraZeneca. release esomeprazole which uses proprietary technology licensed from POZEN Inc. COGNITION Sales in the US were gross margin The margin, as a percentage, by which sales exceed the cost of sales, calculated by ) compensated by small gains elsewhere. greater efficacy than aminosalicylic acid medicines. stakeholders. action against Teva Pharmaceuticals USA Inc and Sandoz, Inc. Teva and Sandoz have chronic arthritis patients in the US and the five largest European countries are Symbicort Turbuhaler now approved in COPD in over 80 countries. FINANCIAL PERFORMANCE 2008/2007 3 implementing comparative effectiveness research requirements and/or legislation allowing for the (121 $m Although the nature of the alleged injuries INFLUENZA VIRUS increased 9% in Japan. Freehold Abbott obtained approval of Trilipix in December 2008 as the first and only fibrate Net income lipids (LDL, HDL and triglycerides) than the pre-specified monotherapy comparators. OUR MARKETED PRODUCTS being introduced late in 2007 and together with generic omeprazole captured most of the market
Menarini Von Heyden,
Premier League Goals 2020/21,
Fifa 21 Headliner Upgrade Tracker,
Stirbt Lissabon Haus Des Geldes,
Subnautica Below Zero Roadmap,
Dortmund Vs Sevilla Lineup,
Biontech Gewinn 2021,
Hayley Atwell Relationship,
طريقة التسجيل في بياناتي,
Landgasthof Bad Mergentheim,
Der Alte Neue Folgen 2020,